Advaxis

Advaxis is a biotechnology company that specializes in the development and commercialization of immunotherapy products. The company is based in Princeton, New Jersey, and was founded in 2002. Advaxis's primary focus is on the development of treatments for cancer and other serious diseases.

History

Advaxis was founded in 2002 by Dr. Thomas A. Moore, a renowned oncologist and immunologist. The company was initially established to commercialize a proprietary Lm Technology, which was developed at the University of Pennsylvania. This technology uses a modified version of the Listeria monocytogenes bacteria to stimulate an immune response against cancer.

Products and Research

Advaxis's primary product is ADXS-HPV, a therapeutic vaccine designed to treat human papillomavirus (HPV)-associated cancers. The vaccine is currently in clinical trials and has shown promising results in early-stage studies.

In addition to ADXS-HPV, Advaxis is also developing several other immunotherapies based on its Lm Technology. These include ADXS-PSA, a treatment for prostate cancer, and ADXS-HER2, a treatment for HER2-positive cancers.

Financials

As a publicly traded company, Advaxis is subject to the financial reporting requirements of the Securities and Exchange Commission (SEC). The company's financial performance is closely watched by investors and analysts in the biotechnology sector.

See also

• Immunotherapy
• Cancer vaccine
• Listeria monocytogenes
• Clinical trial